Literature DB >> 30115699

CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells-Letter.

Martin Thelen1, Axel Lechner2,3, Kerstin Wennhold2, Michael von Bergwelt-Baildon2,4,5,6,7, Hans A Schlößer2,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30115699     DOI： 10.1158/0008-5472.CAN-18-0873

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  11 in total

1.  Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.

Authors:  Xian-Yang Li; Achim K Moesta; Christos Xiao; Kyohei Nakamura; Mika Casey; Haiyan Zhang; Jason Madore; Ailin Lepletier; Amelia Roman Aguilera; Ashmitha Sundarrajan; Celia Jacoberger-Foissac; Clifford Wong; Tracy Dela Cruz; Megan Welch; Alana G Lerner; Bradley N Spatola; Vanessa B Soros; John Corbin; Ana C Anderson; Maike Effern; Michael Hölzel; Simon C Robson; Rebecca L Johnston; Nicola Waddell; Corey Smith; Tobias Bald; Nishamol Geetha; Courtney Beers; Michele W L Teng; Mark J Smyth
Journal:  Cancer Discov       Date:  2019-11-07       Impact factor: 39.397

Review 2.  Targeting CD39 in cancer.

Authors:  Achim K Moesta; Xian-Yang Li; Mark J Smyth
Journal:  Nat Rev Immunol       Date:  2020-07-29       Impact factor: 53.106

3.  Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.

Authors:  Abhishek S Kashyap; Tamara Thelemann; Richard Klar; Sandra M Kallert; Julia Festag; Melanie Buchi; Lisa Hinterwimmer; Monika Schell; Sven Michel; Frank Jaschinski; Alfred Zippelius
Journal:  J Immunother Cancer       Date:  2019-03-12       Impact factor: 13.751

4.  Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Non-small-cell Lung Cancer.

Authors:  Anders Tøndell; Sissel Gyrid Freim Wahl; Anne-Marit Sponaas; Sveinung Sørhaug; Magne Børset; Markus Haug
Journal:  Transl Oncol       Date:  2019-11-13       Impact factor: 4.243

Review 5.  New insights into the interaction of the immune system with non-small cell lung carcinomas.

Authors:  Paul Hofman
Journal:  Transl Lung Cancer Res       Date:  2020-10

6.  Investigating the Potential of Isolating and Expanding Tumour-Infiltrating Lymphocytes from Adult Sarcoma.

Authors:  Alice Ko; Victoria S Coward; Nalan Gokgoz; Brendan C Dickson; Kim Tsoi; Jay S Wunder; Irene L Andrulis
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.639

7.  A Novel Prognostic Biomarker of Luminal Breast Cancer: High CD39 Expression Is Related to Poor Survival.

Authors:  Xiaojian Ni; Wenze Wan; Jingjing Ma; Xinyou Liu; Bohao Zheng; Zhixian He; Weige Yang; Lihong Huang
Journal:  Front Genet       Date:  2021-06-18       Impact factor: 4.599

8.  T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer.

Authors:  Richard A O'Connor; Vishwani Chauhan; Layla Mathieson; Helen Titmarsh; Lilian Koppensteiner; Irene Young; Guilia Tagliavini; David A Dorward; Sandrine Prost; Kevin Dhaliwal; William A Wallace; Ahsan R Akram
Journal:  Oncoimmunology       Date:  2021-07-08       Impact factor: 8.110

Review 9.  On the mechanism of anti-CD39 immune checkpoint therapy.

Authors:  David Allard; Bertrand Allard; John Stagg
Journal:  J Immunother Cancer       Date:  2020-02       Impact factor: 13.751

10.  Increased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AML.

Authors:  F Brauneck; F Haag; R Woost; N Wildner; E Tolosa; A Rissiek; G Vohwinkel; J Wellbrock; C Bokemeyer; J Schulze Zur Wiesch; C Ackermann; W Fiedler
Journal:  Oncoimmunology       Date:  2021-06-21       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.